Armetheon Raises $24.3 Million From Taiwan/China Investors

Armetheon, a San Francisco area specialty biopharma, raised $24.3 million in a Series B funding that will be used to underwrite a Phase III trial of its oral anticoagulant, tecarfarin. Participants in the financing had Taiwan/China connections. The B round was co-led by Hercules Bioventure Partners and Capital TEN II, which are affiliated with Larry Hsu, PhD, a co-founder of Idenix Labs who was born in Taiwan. Other investors included China Development Industrial Bank Healthcare, CDIB & Partners, iD SoftCapital Group of Taiwan and AmKey Ventures. More details.... Stock Symbol: (NDSQ: IDIX) Share this with colleagues: // //  
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.